Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIIB NASDAQ:HALO NASDAQ:INCY NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIIBBiogen$193.76$185.48$121.05▼$205.97$28.61B0.191.21 million shs892,915 shsHALOHalozyme Therapeutics$68.32$65.74$51.06▼$82.22$8.10B0.891.78 million shs1.20 million shsINCYIncyte$97.16$95.41$63.51▼$112.29$19.41B0.791.43 million shs879,786 shsUTHRUnited Therapeutics$568.43$563.25$272.12▼$609.35$24.13B0.6415,129 shs281,045 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIIBBiogen0.00%+0.42%+5.09%-1.31%+54.01%HALOHalozyme Therapeutics0.00%+1.79%+4.53%-3.28%+25.27%INCYIncyte0.00%+1.94%+2.65%-3.66%+51.22%UTHRUnited Therapeutics0.00%-0.03%+0.22%+19.79%+84.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIIBBiogen$193.76$185.48$121.05▼$205.97$28.61B0.191.21 million shs892,915 shsHALOHalozyme Therapeutics$68.32$65.74$51.06▼$82.22$8.10B0.891.78 million shs1.20 million shsINCYIncyte$97.16$95.41$63.51▼$112.29$19.41B0.791.43 million shs879,786 shsUTHRUnited Therapeutics$568.43$563.25$272.12▼$609.35$24.13B0.6415,129 shs281,045 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIIBBiogen0.00%+0.42%+5.09%-1.31%+54.01%HALOHalozyme Therapeutics0.00%+1.79%+4.53%-3.28%+25.27%INCYIncyte0.00%+1.94%+2.65%-3.66%+51.22%UTHRUnited Therapeutics0.00%-0.03%+0.22%+19.79%+84.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIIBBiogen 2.52Moderate Buy$215.6211.28% UpsideHALOHalozyme Therapeutics 2.50Moderate Buy$80.6718.07% UpsideINCYIncyte 2.41Hold$104.007.04% UpsideUTHRUnited Therapeutics 2.85Moderate Buy$619.428.97% UpsideCurrent Analyst Ratings BreakdownLatest HALO, BIIB, UTHR, and INCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026INCYIncyte Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$99.005/21/2026UTHRUnited Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026INCYIncyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$135.005/21/2026INCYIncyte CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026INCYIncyte Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/15/2026BIIBBiogen Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$214.00 ➝ $225.005/15/2026BIIBBiogen EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/14/2026BIIBBiogen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/14/2026BIIBBiogen OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$275.00 ➝ $300.005/12/2026HALOHalozyme Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Buy (B-)5/12/2026HALOHalozyme Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$96.00 ➝ $93.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIIBBiogen$9.89B2.89$22.64 per share8.56$126.33 per share1.53HALOHalozyme Therapeutics$1.40B5.80$4.77 per share14.32$1.85 per share36.93INCYIncyte$5.14B3.78$6.18 per share15.72$28.15 per share3.45UTHRUnited Therapeutics$3.18B7.58$32.99 per share17.23$139.02 per share4.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIIBBiogen$1.29B$9.3220.7911.701.7113.81%12.83%8.01%7/30/2026 (Estimated)HALOHalozyme Therapeutics$316.89M$2.7824.587.430.2823.13%187.91%21.92%8/4/2026 (Estimated)INCYIncyte$1.29B$7.0813.7212.220.9326.71%26.66%19.77%8/4/2026 (Estimated)UTHRUnited Therapeutics$1.33B$27.0920.9817.661.8440.62%19.24%17.25%7/29/2026 (Estimated)Latest HALO, BIIB, UTHR, and INCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026HALOHalozyme Therapeutics$1.54$1.60+$0.06$1.22$358.60 million$376.71 million5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 million4/29/2026Q1 2026BIIBBiogen$2.95$3.57+$0.62$2.15$2.29 billion$2.48 billion4/28/2026Q1 2026INCYIncyte$1.38$1.81+$0.43$1.47$1.22 billion$1.27 billion2/25/2026Q4 2025UTHRUnited Therapeutics$6.78$7.70+$0.92$7.70$814.80 million$790.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBIIBBiogenN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/AINCYIncyteN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIIBBiogen0.343.062.41HALOHalozyme Therapeutics8.812.762.33INCYIncyte0.013.683.60UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIIBBiogen87.93%HALOHalozyme Therapeutics97.79%INCYIncyte96.97%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipBIIBBiogen0.25%HALOHalozyme Therapeutics2.50%INCYIncyte16.20%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIIBBiogen7,500147.64 million147.27 millionOptionableHALOHalozyme Therapeutics390118.61 million115.65 millionOptionableINCYIncyte2,844199.78 million167.42 millionOptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionableHALO, BIIB, UTHR, and INCY HeadlinesRecent News About These CompaniesSwedbank AB Trims Stake in United Therapeutics Corporation $UTHRMay 24 at 7:01 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CFO Sells $5,641,100.00 in StockMay 23 at 7:50 AM | insidertrades.comUnited Therapeutics Corporation $UTHR Holdings Decreased by LSV Asset ManagementMay 23 at 6:39 AM | marketbeat.comMeiji Yasuda Asset Management Co Ltd. Grows Stock Position in United Therapeutics Corporation $UTHRMay 23 at 5:49 AM | marketbeat.comPaul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) StockMay 23 at 4:11 AM | americanbankingnews.comBanque Cantonale Vaudoise Acquires New Stake in United Therapeutics Corporation $UTHRMay 23 at 3:35 AM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells 10,000 Shares of StockMay 22 at 7:12 PM | marketbeat.comUnited Therapeutics Explores Pig Heart Transplants And Space Labs As Valuation LagsMay 22 at 1:42 PM | finance.yahoo.comInsider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of StockMay 22 at 7:29 AM | insidertrades.comJ.P. Morgan Keeps Their Buy Rating on United Therapeutics (UTHR)May 21, 2026 | theglobeandmail.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of StockMay 20, 2026 | insidertrades.comQuant ratings on Renaissance Technologies' top holdings: UTHR, PLTR, AAPLMay 20, 2026 | seekingalpha.comUTHR holds as Tyvaso shows 33% lower worsening risk in rare lung scarring diseaseMay 20, 2026 | msn.comUnited Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 SharesMay 19, 2026 | marketbeat.comUnited Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19, 2026 | seekingalpha.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of StockMay 19, 2026 | americanbankingnews.comUnited Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026May 18, 2026 | businesswire.comHC Wainwright Issues Pessimistic Outlook for UTHR EarningsMay 18, 2026 | americanbankingnews.comHC Wainwright Has Negative Estimate for UTHR Q2 EarningsMay 18, 2026 | marketbeat.comUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026May 17, 2026 | businesswire.comLeuthold Group LLC Buys 3,126 Shares of United Therapeutics Corporation $UTHRMay 17, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026Biogen Stock Slides After Trial Miss, But Analysts Stay BullishBy Chris Markoch | May 22, 2026HALO, BIIB, UTHR, and INCY Company DescriptionsBiogen NASDAQ:BIIB$193.76 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$193.50 -0.26 (-0.13%) As of 05/22/2026 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.Halozyme Therapeutics NASDAQ:HALO$68.32 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$68.64 +0.32 (+0.47%) As of 05/22/2026 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Incyte NASDAQ:INCY$97.16 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$97.14 -0.02 (-0.03%) As of 05/22/2026 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.United Therapeutics NASDAQ:UTHR$568.43 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$568.09 -0.34 (-0.06%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
